{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:09:50Z","timestamp":1794668990187,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.antiviral.2026.106533","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:56:20Z","timestamp":1789397780000},"page":"106533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-313X","authenticated-orcid":false,"given":"Venice","family":"Du Pont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Vijjapurapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandita","family":"Parhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7201-533X","authenticated-orcid":false,"given":"Kristen","family":"Andreatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-2370","authenticated-orcid":false,"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6395-3093","authenticated-orcid":false,"given":"Caleb","family":"Marceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106533_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104807","article-title":"Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice","volume":"179","author":"Abed","year":"2020","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106533_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.antiviral.2026.106533_bib3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-063775","article-title":"Remdesivir for COVID-19 in hospitalized children: a phase 2\/3 study","volume":"153","author":"Ahmed","year":"2024","journal-title":"Pediatrics"},{"issue":"19","key":"10.1016\/j.antiviral.2026.106533_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106533_bib5","doi-asserted-by":"crossref","DOI":"10.5808\/GI.2020.18.4.e44","article-title":"Spike protein D614G and RdRp P323L: the SARS-CoV-2 mutations associated with severity of COVID-19","volume":"18","author":"Biswas","year":"2020","journal-title":"Genomics Inform"},{"key":"10.1016\/j.antiviral.2026.106533_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.antiviral.2026.106533_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00198-22","article-title":"In vitro selection of remdesivir-resistant SARS-CoV-2 demonstrates high barrier to resistance","volume":"66","author":"Checkmahomed","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.antiviral.2026.106533_bib8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106533_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70340","article-title":"Phenotypic characterization of replication-impaired lenacapavir-resistant HIV clinical isolates","volume":"97","author":"Demirdjian","year":"2025","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2026.106533_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsinfecdis.5b00053","article-title":"High-throughput minigenome system for identifying small-molecule inhibitors of ebola virus replication","volume":"1","author":"Edwards","year":"2015","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106533_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/v16030388","article-title":"Impact of the H274Y substitution on N1, N4, N5, and N8 neuraminidase enzymatic properties and expression in reverse genetic influenza A viruses","volume":"16","author":"Gaymard","year":"2024","journal-title":"Viruses"},{"issue":"19","key":"10.1016\/j.antiviral.2026.106533_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13059-023-02881-5","article-title":"The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection","volume":"24","author":"Goldswain","year":"2023","journal-title":"Genome Biol."},{"issue":"10","key":"10.1016\/j.antiviral.2026.106533_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2009.297","article-title":"Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus","volume":"301","author":"Gooskens","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-026-09844-z","article-title":"Preferential remdesivir triphosphate incorporation by SARS-CoV-2 polymerase is altered to ATP by the S759A mutation","volume":"9","author":"Gordon","year":"2026","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106533_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106533_bib18","article-title":"A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance","volume":"14","author":"Grimes","year":"2023","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.antiviral.2026.106533_bib19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 adaptive COVID-19 treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2026.106533_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/v16040546","article-title":"No remdesivir resistance observed in the phase 3 severe and moderate COVID-19 SIMPLE trials","volume":"16","author":"Hedskog","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib21","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-024-47941-x","article-title":"Dynamic diversity of SARS-CoV-2 genetic mutations in a lung transplantation patient with persistent COVID-19","volume":"15","author":"Igari","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106533_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0166-3542(02)00053-0","article-title":"The H274Y mutation in the influenza A\/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo","volume":"55","author":"Ives","year":"2002","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106533_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jinf.2009.07.002","article-title":"Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation","volume":"59","author":"Kawai","year":"2009","journal-title":"J. Infect."},{"issue":"9","key":"10.1016\/j.antiviral.2026.106533_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113077","article-title":"SARS-CoV-2 variants with NSP12 P323L\/G671S mutations display enhanced virus replication in ferret upper airways and higher transmissibility","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2026.106533_bib25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2147\/IDR.S295060","article-title":"The occurrence of rtA194T mutant after long-term lamivudine monotherapy remains sensitive to tenofovir disoproxil fumarate: a case report","volume":"14","author":"Li","year":"2021","journal-title":"Infect. Drug Resist."},{"issue":"9","key":"10.1016\/j.antiviral.2026.106533_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00602-21","article-title":"Key metabolic enzymes involved in remdesivir activation in human lung cells","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"494","key":"10.1016\/j.antiviral.2026.106533_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9242","article-title":"Remdesivir (GS-5734) protects African green monkeys from nipah virus challenge","volume":"11","author":"Lo","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2026.106533_bib28","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106533_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","article-title":"Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years","volume":"231","author":"Margot","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106533_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105033","article-title":"Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir","volume":"188","author":"Martin","year":"2021","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.antiviral.2026.106533_bib31","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106533_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2017.08.005","article-title":"An RNA polymerase II-driven ebola virus minigenome system as an advanced tool for antiviral drug screening","volume":"146","author":"Nelson","year":"2017","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2026.106533_bib33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2026.106533_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 retain antiviral activity against Delta, omicron, and other emergent SARS-CoV-2 variants","volume":"66","author":"Pitts","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106533_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/v18020255","article-title":"Antiviral activity of remdesivir and obeldesivir against SARS-CoV-2 omicron subvariants that were circulating from September 2023 through June 2025","volume":"18","author":"Rodriguez","year":"2026","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.antiviral.2026.106533_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/v17020168","article-title":"Remdesivir and obeldesivir retain potent antiviral activity against SARS-CoV-2 omicron variants","volume":"17","author":"Rodriguez","year":"2025","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.antiviral.2026.106533_bib38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"656","key":"10.1016\/j.antiviral.2026.106533_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-Dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.antiviral.2026.106533_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.antiviral.2026.106533_bib41","doi-asserted-by":"crossref","first-page":"13019","DOI":"10.1093\/nar\/gkab1160","article-title":"The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme","volume":"49","author":"Walker","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"7594","key":"10.1016\/j.antiviral.2026.106533_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.antiviral.2026.106533_bib43","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41596-021-00491-8","article-title":"Engineering SARS-CoV-2 using a reverse genetic system","volume":"16","author":"Xie","year":"2021","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.antiviral.2026.106533_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.antiviral.2013.08.018","article-title":"In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons","volume":"100","author":"Yu","year":"2013","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2026.106533_bib45","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42003-023-05451-4","article-title":"Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor","volume":"6","author":"Yu","year":"2023","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.antiviral.2026.106533_bib46","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001583","article-title":"SARS-CoV-2 replicon for high-throughput antiviral screening","volume":"102","author":"Zhang","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2026.106533_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:22:31Z","timestamp":1794086551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S0166354226001920"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106533","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106533"}}